PBYI | Woo Trader

CPBYI - Puma Biotechnology, Inc.

Puma Biotechnology, Inc. is a biopharmaceutical company focused on the acquisition, in-licensing, development and commercialization of novel therapeutics for the treatment of cancer. Its products under development include PB272 (oral neratinib) for the treatment of patients with human epidermal growth factor receptor type 2 (HER2) positive metastatic breast cancer and gastric cancer and PB272 (neratinib intravenous) for the treatment of patients with advanced cancer. Puma Biotechnology, Inc. is headquartered in Los Angeles, California.

Last Close	$41.90^-1.76%	Range	$41.55-$42.85
Volume	685,900^-32%	Market Cap	$1.57 B
Avg Daily $	$42.53 M	Avg Volume	1.02 M
52 Week High	$136.90^-69%	52 Week Low	$41.30^+1%
Insider Score	Medium Selling	%Insiders	21.5%
%Institutions	101.55%	%M.F.	34.58%
Price Target	$108.83^+160%	Mean Rating	Outperform
Zacks Target	$102.83^+145%	Zacks Rating	Buy
TR Target	$76.00^+81%	TR Rating	Buy
News/Blogs	0.01^+111%	With Impact	0.01^+116%
Next Earnings	2018-11-08	Forward EPS	‑$1.09
EPS	-5.6	P/E	-7.48
Dividend	N/A	Yield	N/A

Wootrader.com is moving to https://financeboards.com - sign up for a free account.

CPBYI - Puma Biotechnology, Inc.

This full content is available for membership level Budding Investor or higher. You can register for a new account now.